One approach to help reduce the burden of malaria caused by Plasmodium falciparum is intermittent preventive treatment (IPT), which involves periodic therapeutic doses of antimalarials to reduce the incidence of malaria and prevalence of anemia [1],[2].
The intensity of the contacts with P. falciparum seems to represent the main factor influencing anti-schizont IgG responses.
Molecular typing revealed effects of the intervention not detected by ordinary microscopy. Effective seasonal IPT temporarily reduced the prevalence and genetic diversity of P. falciparum infections.
In the global context of a reduction of under-five mortality, neonatal mortality is an increasingly relevant component of this mortality. Malaria in pregnancy may affect neonatal survival, though no strong evidence exists to support this association.
Intermittent preventive treatment in infants (IPTi) is a new malaria control tool. This study investigated how protection against malaria given by SP, chlorproguanil-dapsone (CD) and mefloquine (MQ), varied with time since administration of IPTi.
We discuss IPT with SP in light of several concerns and highlight recent findings from a pharmacokinetic study of SP in this population.
This study explored the potential of a strategy of intermittent preventive treatment for children (IPTC) and timely treatment of malaria-related febrile illness in the home in reducing the parasite prevalence and malaria morbidity in young children in a coastal village in Ghana.
Administration of sulfadoxine-pyrimethamine at times of vaccination—intermittent preventive treatment in infants (IPTi)—is a promising strategy to prevent malaria. However, rising resistance to this combination is a concern. We investigated a shortacting and longacting antimalarial drug as alternative regimens for IPTi.
Intermittent preventive treatment in infants (IPTi) is an effective and safe malaria control strategy. However, it remains unclear what antimalarials should be used to replace sulfadoxine-pyrimethamine (SP) when and where SP is no longer an effective drug for IPTi.
Access and compliance to sulfadoxine–pyrimethamine (SP) for intermittent preventive treatment of malaria in pregnancy (IPTp) when delivered by community-directed drug distributors (CDDs) of ivermectin for onchocerciasis control (intervention arm) and through delivery of SP–IPTp during antenatal care visit (control arm) was investigated in western Uganda.
